Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma

International Journal of Cancer

Volumn 119, Issue 5, 2006, Pages 1039-1046

  Benini, Stefania ^a   Zuntini, Monia ^a   Manara, Maria Cristina ^a   Cohen, Pinchas ^b   Nicoletti, Giordano ^a,c   Nanni, Patrizia ^c   Oh, Youngman ^d   Picci, Piero ^a   Scotlandi, Katia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b MATTEL CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Ewing's sarcoma; Insulin like growth factor; Insulin like growth factor binding protein 3

Indexed keywords

COMPLEMENTARY DNA; GELATINASE B; RNA; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; SARCOMA, EWING'S; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746374074     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21929     Document Type: Article

References (37)

1. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N. Blockage of insulin-like growth factor-I receptor inhibits the growth of ES in athymic mice. Cancer Res 1998;58:4127-31.
2. Scotlandi K, Maini C, Manara MC, Benini S, Serra M, Cerisano V, Strammiello R, Baldini N, Lollini PL, Nicoletti G, Picci P. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002;9:296-307.
3. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
4. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19:5574-81.
5. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGFdependent and -independent mechanisms. J Endocrinology 2002;175:19-31.
6. AH O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 2003;35:726-33.
7. Lee HY, Moon H, Chun KH, Chand YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. Natl Cancer Inst 2004;96:1536-48.
8. Kirman I, Poltoratskaia N, Sylla P, Whelan RL. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery 2004;136:205-9.
9. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
10. Petridou E, Skalkidou A, Dessypris N, Moustaki M, Mantzoros C, Spanos E, Trichopoulos D. Insulin-like growth factor binding protein-3 predicts survival from acute childhood leukemia. Oncology 2001;60:252-7.
11. Renehanw AG, Zẇahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
12. Scotlandi K, Benini S, Sarti M, Serra M, Lollini P-L, Maurici D, Picci P, Triche TJ, Baldini N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
13. Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG, Larsson O. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene 2000;19:4298-301.
14. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 2001;20:626-33.
15. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V, Burchill SA. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11:2364-78.
16. de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindan FJ, Barr FG, Ladanyi M. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000;156:849-55.
17. Toretzky JA, Kalebic T, Blakesley V, Le Roith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7.
18. Prieur A, Tirade F, Cohen P, Delattre O. EWS/FLI1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biology 2004;24:7275-83.
19. Benini S, Manara MC, Baldini N, Cerisano V, Serra M, Mercuri M, Lollini P-L, Nanni P, Picci P, Scotlandi K. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7:1790-7.
20. Strammiello R, Benini S, Manara MC, Perdichizzi S, Serra M, Spisni E, Picci P, Scotlandi K. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 2003;11/12:675-84.
21. Scotlandi K, Manara MC, Nicoletti G, Lollini P-L, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
22. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, et al. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 2002;160:849-59.
23. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffter HP, Cohen P. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 2004;279(1):469-76.
24. Dunn SE, Hardman RA, Kari FW, Barrett CJ. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-93.
25. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
26. Chakravarti A, Loeffter JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
27. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Pica P, Serra M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41:1349-61.
28. Manara MC, Perdichizzi S, Serra M, Pierini R, Hattinger CM, Benini S, Astolfi A, Zaffaroni M, D'Incalci M, Scotlandi K, Picci P. Molecular mechanisms responsible for the resistance to ET-743 (Trabectidin; Yondelis) in Ewing's sarcoma cells. Int J Oncol 2005;27:1605-16.
29. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, Perdichizzi S, Lollini PL, De Giovanni C, Landuzzi L, Picci P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002;101:11-6.
30. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
31. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578. T human breast cancer cells. J Biol Chem 1993;268:26045-8.
32. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997;272:25602-7.
33. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 2000;88:336-4.
34. Spagnoli A, Hwa V, Horton WA, Lunstrum GP, Roberts CT, Jr, Chiarelli F, Torello M, Rosenfeld RG. Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1. C5.18. relationship to differentiation stage. J Biol Chem 2001;276:5533-40.
35. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Choen P. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000;275:33607-13.
36. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 2005;280:16942-8.
37. Zhang D, Bar-Eli M, Meloche S, Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004;279:19683-90.